Drisapersen (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Drisapersen" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

1^st place

79^th place

65^th place

low place

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

38^th place

40^th place

719^th place

636^th place

low place

low place

low place

low place

low place

low place

bmrn.com (Global: low place; English: low place)

investors.bmrn.com

"BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe (NASDAQ:BMRN)". investors.bmrn.com. Archived from the original on 2016-06-04. Retrieved 2016-06-09.

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

Clinical trial number NCT01254019 for "A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)" at ClinicalTrials.gov

gsk.com (Global: low place; English: low place)

"Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)" (Press release). GlaxoSmithKline. 13 January 2014. Archived from the original on 19 May 2014. Retrieved 2014-06-13.

medscape.com (Global: 719^th place; English: 636^th place)

"Positive New Results for Eteplirsen, Drisapersen in DMD". Medscape. May 15, 2014. Retrieved 2014-06-13.

prosensa.eu (Global: low place; English: low place)

"PRO051/GSK2402968". Prosensa. Archived from the original on July 29, 2012. Retrieved 29 October 2012.
"Pipeline" (Press release). Archived from the original on 2014-08-17. Retrieved 2014-06-13.

raredr.com (Global: low place; English: low place)

"FDA Accepts Sarepta's NDA for Eteplirsen". Rare Disease Report. Archived from the original on 2015-08-28. Retrieved 2015-08-28.

web.archive.org (Global: 1^st place; English: 1^st place)

"PRO051/GSK2402968". Prosensa. Archived from the original on July 29, 2012. Retrieved 29 October 2012.
"Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)" (Press release). GlaxoSmithKline. 13 January 2014. Archived from the original on 19 May 2014. Retrieved 2014-06-13.
"Pipeline" (Press release). Archived from the original on 2014-08-17. Retrieved 2014-06-13.
"FDA Accepts Sarepta's NDA for Eteplirsen". Rare Disease Report. Archived from the original on 2015-08-28. Retrieved 2015-08-28.
"BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe (NASDAQ:BMRN)". investors.bmrn.com. Archived from the original on 2016-06-04. Retrieved 2016-06-09.

wsj.com (Global: 79^th place; English: 65^th place)

"BioMarin to Pay Up to $840 Million for Prosensa". Wall Street Journal. 24 November 2014. Retrieved 2015-11-05.
"Setback for Drug Made by Glaxo, Prosensa". Wall Street Journal. 20 September 2013. Retrieved 2013-09-20.
Walker J (Nov 24, 2014). "BioMarin to Pay Up to $840 Million for Prosensa". Wall Street Journal.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

"FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus". Yahoo Finance. 14 January 2016.